B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

AKR1B1

MOLECULAR TARGET

aldo-keto reductase family 1 member B1

UniProt: P07943NCBI Gene: 2419214 compounds

AKR1B1 (aldo-keto reductase family 1 member B1) is targeted by 14 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting AKR1B1

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Quercetin2.7114
2Emodin Purgative anthraquinone found in several plants, especially RHAMNUS PURSHIANA. It was formerly used as1.614
3Chlorogenic Acid1.393
4Luteolin 5,7,3',4'-tetrahydroxy-flavone,1.393
5chrysin1.102
6Kaempferols1.102
7Rosmarinic Acid1.102
8Apigenin 5,7,4'-trihydroxy-flavone,0.691
9butein0.691
10Glyceraldehyde0.691
11Indomethacin0.691
12Sulindac0.691
13Tolmetin0.691
14Pennisetum0.691

About AKR1B1 as a Drug Target

AKR1B1 (aldo-keto reductase family 1 member B1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 14 compounds with documented AKR1B1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

AKR1B1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.